Solventum Corporation (SOLV)

NYSE • Healthcare

$85.41

-$2.04 (-2.3%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$86.92

Previous Close$85.41

Day Range$84.81 - $87.27

Avg. Volume (3M)990.9K

Market Cap$14.5B

P/E Ratio10.4

52 Week Range

$62.38$94.16

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$2.2B100%

Gross Profitminus cost of goods$1.2B58%

Operating Incomeminus R&D and overhead$181M8%

Net Incomeminus taxes and the rest$92M4%

In plain terms: out of every $100 in revenue, Solventum Corporation keeps $4 as net profit.

Fundamentals & Financials

Revenue (TTM)

$8.3B

Net Income (TTM)

$1.4B

EPS (TTM)

$8.22

ROA (TTM)

10.07%

Current Ratio

1.02

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+16.6%Q3 2025$1.69

+4.9%Q4 2025$1.5

+4.7%Q1 2026$1.57

+9.6%Q2 2026$1.48

+34.2%Q3 2026$2.55

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +34.2%

Solventum beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 5, as revenue and adjusted EPS both came in above consensus. Revenue rose 2% to about $2.2 billion, topping the about $2.2 billion estimate by about 3%, while adjusted EPS of $2.55 beat the $1.90 forecast by about 34% and improved from $1.69 a year earlier. Net income rose 2% to roughly $92.0 million from $90.0 million a year ago, with gross margin near 58% and operating margin around 8% on operating income of about $181 million. Operating cash flow came in at $38.0 million, and the company repurchased about $355.0 million of stock.

Next report — what to expect

Solventum Corporation (SOLV) is scheduled to report earnings on November 5, 2026. Wall Street consensus calls for EPS of $1.35 on revenue of $1.93 billion. For trailing context, revenue grew +2.2% year over year last quarter. Solventum has beaten EPS in 8 of 8 most recent quarters.

View full earnings history

About Solventum Corporation

Solventum Corporation is a healthcare company listed on the NYSE under SOLV that sells medical devices, dental and orthodontic products, clinical and revenue-cycle software, and filtration technologies across care settings and healthcare workflows. Across these businesses, Solventum generated $8.3 billion in revenue in FY2025.

Name

Solventum Corporation

CEO

Bryan C. Hanson

Website

www.solventum.com

Industry

Healthcare

Year Founded

2023

Employees

20,584

Today's Snapshot

AI-generated

SOLV closed 2.3% lower on heavier trading than usual. Solventum won FDA clearance to combine Restrata, a wound matrix, with V.A.C. Therapy. SOLV is due to report earnings on 5 November.

Trading Volume

Above 10d avg 1.1M

1.6M

vs S&P 500 Today

Underperforming Market

-1.81%

Updated: October 23, 2026 at 20:20 UTC

SOLV Headlines

Mixed Global Markets and Key Corporate Moves

February 11, 2026

6 min read

View All News

Technical Indicators

2 Buy2 Neutral4 Sell

SOLV is displaying short-term weakness as the price trades beneath several short- and medium-term averages while MACD and momentum are negative, pointing to selling pressure. ADX is low, indicating the downmove lacks strong directional conviction, and ATR shows only moderate volatility. Notably, longer-term averages sit below the current price, so the weakness is concentrated in shorter timeframes, and on-balance volume is positive which tempers the signal. The pivot sits above the market as nearby resistance. Technical takeaway: Sell — short/medium-term moving averages and bearish MACD favor sellers, despite the price remaining above longer-term averages.

All signals